legislation: 114-s-3466

Congressional bills and resolutions from Congress.gov, filtered to policy areas relevant to environmental, health, agriculture, and wildlife regulation.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

bill_id congress bill_type bill_number title policy_area introduced_date latest_action_date latest_action_text origin_chamber sponsor_name sponsor_state sponsor_party sponsor_bioguide_id cosponsor_count summary_text update_date url
114-s-3466 114 s 3466 Accelerating New Pharmaceutical Competition Act Health 2016-09-29 2016-09-29 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Senate Sen. Paul, Rand [R-KY] KY R P000603 0 Accelerating New Pharmaceutical Competition Act This bill amends the Federal Food, Drug, and Cosmetic Act to permit brand name drug applications to rely upon investigations conducted in certain foreign countries if the drug has been approved in the foreign country where the investigations were conducted. The Food and Drug Administration (FDA) has 90 days to act on these applications. The bill revises a provision regarding the effective date of the approval of a generic drug that is subject to a patent infringement action. The FDA must prioritize the review of, and act within 150 days on, generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications. 2023-01-11T13:34:07Z  

Links from other tables